AAIC 2026 highlighted the transformative role of biomarkers in Alzheimer's disease (AD) clinical trials, from patient selection to outcome measures and regulatory approval. Biomarker-guided approaches are now essential for efficient trial design and successful therapeutic development.
Selecting patients based on biomarker confirmation:
- Anti-amyloid trials: Requiring amyloid PET positivity or CSF biomarker evidence
- Impact on trial efficiency: Reduced sample sizes and shorter trial durations
- Diversity considerations: Ensuring biomarker criteria don't exclude diverse populations
Utilizing tau pathology for patient stratification:
- Baseline tau burden: Predicting treatment response
- Regional tau targeting: Matching patients to specific mechanisms
- Tau spread patterns: Identifying therapeutic targets
Revolutionizing trial recruitment:
- Pre-screening with p-Tau217/p-Tau181: Identifying amyloid-positive individuals
- Reducing screening failure rates: Up to 70% reduction in screen failures
- Cost implications: Significant cost savings in recruitment
Measuring biological effects of anti-amyloid therapies:
- PET amyloid reduction: Centiloid change as endpoint
- CSF biomarker changes: Aβ42/40 ratio normalization
- Time course: Relationship between amyloid removal and clinical outcomes
Emerging tau-focused endpoints:
- Tau PET change: Regional tau burden modification
- Fluid tau biomarkers: p-Tau changes as surrogate
- Neurodegeneration markers: NfL as downstream marker
General markers of disease modification:
- Brain atrophy rates: MRI volumetric changes
- Neurofilament light chain: NfL as marker of neuronal injury
- Synaptic biomarkers: SV2A PET, NPTX1
Flexible trial designs incorporating biomarker data:
- Sample size re-estimation: Based on biomarker effect size
- Arm dropping: Eliminating non-effective doses
- Enrichment adaptations: Focusing on responsive subgroups
Master protocol approaches:
- MASTER AD protocol: Multi-arm platform for AD
- Adaptive randomization: Based on interim biomarker results
- Efficient resource utilization: Shared control arms
Regulatory acceptance of biomarkers:
- Accelerated approval: Using amyloid PET as surrogate endpoint
- Clinical trial endpoints: Biomarker changes supporting approval
- Label expansions: Including biomarker data in prescribing information
European regulatory considerations:
- Biomarker qualification: Pathway for novel biomarkers
- Conditional approvals: Based on biomarker evidence
- Post-marketing requirements: Continued biomarker monitoring
Recent trial results with biomarker endpoints:
- Leucanemab (Leqembi): CLARITY-AD biomarker findings
- Donanemab (Kisunla): TRAILBLAZER-ALZ 2 biomarker data
- Aduhelm legacy: Lessons learned from approval process
Tau-targeted approaches:
- Active vaccination: ACI-35 and other tau vaccines
- Passive immunization: Anti-tau antibodies
- Small molecule inhibitors: Tau aggregation blockers
Disease-modifying approaches beyond amyloid and tau:
- TREM2 modulators: Microglial-targeted therapies
- Neuroinflammation inhibitors: Anti-inflammatory approaches
- Synaptic protection: Synaptic resilience strategies
Multiple pathways require multiple interventions:
- Amyloid + tau: Targeting both pathologies
- Pathology + neuroprotection: Comprehensive approaches
- Personalized combinations: Based on individual biomarker profiles
Optimizing combination therapy:
- Biomarker interactions: Effects of combinations on multiple targets
- Safety monitoring: Biomarker-guided safety assessments
- Dosing optimization: Adaptive dosing based on biomarkers
Targeting biomarker-defined subtypes:
- By amyloid status: Sporadic vs. autosomal dominant AD
- By tau pattern: Regional tau subtypes
- By comorbidities: Vascular, Lewy body comorbidities
Individualized therapeutic approaches:
- N-of-1 trials: Single-patient optimization
- Biomarker trajectories: Individual response patterns
- Adaptive sequencing: Sequential treatments based on biomarkers
Economic implications of biomarker-guided care:
- Early diagnosis cost savings: Downstream cost reductions
- Treatment efficiency: Better allocation of expensive therapies
- Prevention cost-effectiveness: Investing in early intervention
Post-approval biomarker monitoring:
- Registry data: Long-term biomarker outcomes
- Clinical practice biomarkers: Real-world implementation
- Health economic models: Population-level impacts
New markers in development:
- Synaptic dysfunction markers: Direct measurement of synaptic loss
- Cellular senescence markers: Senolytic targets
- Microbiome markers: Gut-brain axis biomarkers
Next-generation approaches:
- Preventive trials: Initiating treatment in preclinical stages
- Outcome measure innovation: Novel clinical and biomarker composites
- Global trial networks: International collaboration
This page provides information about AAIC 2026: Biomarker-Guided Clinical Trials.